BLOG: Restasis and bioequivalence

We interrupt this well-designed linear discussion of dry eye syndrome to bring you an important announcement: Allergan has challenged the U.S. Food and Drug Administration in support of Restasis.You are probably thinking something along the lines of, “Duh, of course it is,” because Restasis (cyclosporine ophthalmic emulsion 0.05%) is about to lose patent protection, but openly challenging the FDA is a “man bites dog” event. More importantly, the outcome of this battle will affect every one of us manning the front line of dry eye syndrome (DES) treatment and probably every difficult-to-manufacture (Read more...)

Full Story →